Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.60 USD
Change Today +0.13 / 5.26%
Volume 29.3K
NSPH On Other Exchanges
Symbol
Exchange
NSPH is not on other exchanges.
As of 12:54 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

nanosphere inc (NSPH) Snapshot

Open
$2.45
Previous Close
$2.47
Day High
$2.60
Day Low
$2.45
52 Week High
10/13/14 - $25.40
52 Week Low
08/24/15 - $2.06
Market Cap
19.1M
Average Volume 10 Days
51.6K
EPS TTM
$-8.08
Shares Outstanding
7.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOSPHERE INC (NSPH)

Related News

No related news articles were found.

nanosphere inc (NSPH) Related Businessweek News

No Related Businessweek News Found

nanosphere inc (NSPH) Details

Nanosphere, Inc. develops, manufactures, and markets molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment, and enhanced healthcare economics. It offers a molecular diagnostics platform, Verigene System platform that enables clinicians to identify and treat the bacteria and viruses for complex, costly, and deadly infectious diseases. The Verigene System includes a bench-top molecular diagnostics workstation for genomic and protein testing. The Verigene System is used for testing infectious disease assays, human and pharmacogenetic assays, and ultra-sensitive protein assays. The company focuses on serving hospital-based laboratories and academic research institutions in the United States. Nanosphere, Inc. was founded in 1998 and is headquartered in Northbrook, Illinois.

169 Employees
Last Reported Date: 02/11/15
Founded in 1998

nanosphere inc (NSPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $330.0K
Chief Strategy Officer
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2014.

nanosphere inc (NSPH) Key Developments

Nanosphere, Inc. Announces Unaudited Earnings Results for the Second Quarter Ended June 30, 2015; Reaffirms Revenue Guidance for 2015

Nanosphere, Inc. announced unaudited earnings results for the second quarter ended June 30, 2015. Nanosphere achieved record revenues for the second quarter 2015, of $4.7 million compared to $2.7 million in the second quarter 2014. This 76% year-over-year revenue growth was driven by U.S. based microbiology laboratories' continued adoption of Gram Positive (BCGP) and Gram Negative (BCGN) blood culture tests, which grew more than 87% over second quarter of 2014. Net loss for the second quarter of 2015 was $8.6 million, as compared to $10.0 million in the second quarter of 2014. Loss from operations was $7,741,000 against $9,684,000 a year ago. Net loss per common share - basic and diluted was $2.25 against $2.65 a year ago. For the six months, total revenue was $9,336,000, loss from operations was $14,987,000 and net, and comprehensive loss was $16,127,000 or $3.58 per basic and diluted share against total revenue of $5,955,000, loss from operations of $19,290,000 and net, and comprehensive loss of $20,016,000 or $5.28 per basic and diluted share for the same period a year ago. The company also confirmed full year revenue guidance for 2015 of $18 to $20 million.

Nanosphere, Inc. Amends Certain Terms of Its $30 Million Term Loan Facility with NSPH Funding LLC

Nanosphere, Inc. announced that it has amended certain terms of its $30 million term loan facility with NSPH Funding LLC, an affiliate of Life Sciences Alternative Funding LLC, and SWK Funding LLC, as lenders. Nanosphere entered into the loan facility and immediately drew $20 million under the facility on May 14, 2015. Under the original terms of the loan facility, Nanosphere was subject to a condition precedent and a post-closing covenant that required Nanosphere to raise an aggregate of at least $4 million in net proceeds from equity financings prior to entering into the loan facility and an aggregate of at least $6 million in net proceeds either equity financings or licensing or strategic partnership transactions within eight months of May 14, 2015, pursuant to which Nanosphere raised an aggregate of $8 million in net proceeds from its preferred stock offerings in May and June 2015. Under the amended terms of the loan facility, the lenders have waived the requirement that Nanopshere raise an additional $2 million in consideration of certain adjustments to the reserve requirements under the loan facility.

Nanosphere, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Nanosphere, Inc. announced that they will report Q2, 2015 results on Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPH:US $2.60 USD +0.13

NSPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $10.07 USD +0.64
Great Basin Scientific Inc $0.37 USD -0.0095
Meridian Bioscience Inc $19.21 USD +0.49
Quidel Corp $20.46 USD -0.2405
T2 Biosystems Inc $12.09 USD +0.03
View Industry Companies
 

Industry Analysis

NSPH

Industry Average

Valuation NSPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSPHERE INC, please visit www.nanosphere.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.